|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07K 16/28 | |
| A61K 47/68 | |||
| A61P 35/00 |
| (11) | Patento numeris | 3371223 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 16810243.2 |
| Europos patento paraiškos padavimo data | 2016-10-27 | |
| (97) | Europos patento paraiškos paskelbimo data | 2018-09-12 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-03-10 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2016/001791 |
| Data | 2016-10-27 |
| (87) | Numeris | WO 2017/076492 |
| Data | 2017-05-11 |
| (30) | Numeris | Data | Šalis |
| 15192851 | 2015-11-03 | EP | |
| 16178010 | 2016-07-05 | EP |
| (72) |
DOERNER, Achim, DE
TOLEIKIS, Lars, DE
SOOD, Vanita, D., CA
SELLMANN, Carolin, DE
KNUEHL, Christine, DE
|
| (73) |
Merck Patent GmbH,
Frankfurter Strasse 250, 64293 Darmstadt,
DE
|
| (54) | BI-SPECIFIC ANTIBODIES FOR ENHANCED TUMOR SELECTIVITY AND INHIBITION AND USES THEREOF |
| BI-SPECIFIC ANTIBODIES FOR ENHANCED TUMOR SELECTIVITY AND INHIBITION AND USES THEREOF |